Inclusion Criteria:

- Histologically confirmed invasive squamous cell carcinoma of the head and neck

- Inoperable tumor or the patient is not a candidate for surgery for medical reasons;
prior surgery may or may not have been done

- Prior radiotherapy or chemoradiotherapy has been given to the tumor

- If prior 18F-boronophenylalanine (BPA) PET (positron emission tomography)has been
done, BPA needs to accumulate at least 2 times more in the tumor than in the
corresponding normal tissue

- A written informed consent

Exclusion Criteria:

- Presence of distant metastases

- A non-experimental, effective treatment op-tion is available

- WHO performance status >3

- WBC <2,500/mm3, platelets <75,000/mm3, serum creatinine >180 umol/L

- Concomitant systemic cancer chemotherapy (except cetuximab).

- Other concurrent experimental therapy

- Less than 1 month since prior radiation therapy

- Untreated or severe treated congestive heart failure or renal failure

- A cardiac pace-maker or unremovable metal implants present in the head and neck
region that will interfere with MRI-based dose-planning

- Restlessness or inability to lie in a cast for 30 to 60 minutes

- Clinical follow-up after therapy cannot be arranged or the patient is not willing to
participate in follow-up

- Pregnancy

- Age less than 18

- Known allergy/hypersensitivity to cetuximab